Cell Therapy News Volume 22.40 | Nov 22 2021

    0
    115







    2021-11-22 | CTN 22.40


    Cell Therapy News by STEMCELL Technologies
    Vol. 22.40 – 22 November, 2021
    TOP STORY

    Systemic IL-15 Promotes Allogeneic Cell Rejection in Patients Treated with Natural Killer Cell Adoptive Therapy

    Scientists hypothesized that the mechanism responsible for MHC-haploidentical NK cell therapy for relapsed/refractory AML was IL-15/N-803 promoting recipient CD8 T cell activation that in turn accelerated donor NK cell rejection.
    [Blood]

    Abstract
    Request your free copy of the 'Directed Differentiation of Pluripotent Stem Cells' Wallchart
    PUBLICATIONSRanked by the impact factor of the journal

    T Lymphocyte-Captured DNA Network for Localized Immunotherapy

    The authors reported a cell capture DNA network containing polyvalent multimodules for the specific isolation and in situ incubation of T lymphocytes.
    [Journal of the American Chemical Society]

    AbstractGraphical Abstract

    Localized Drug Delivery Graphene Bioscaffolds for Cotransplantation of Islets and Mesenchymal Stem Cells

    Researchers developed, characterized, and tested an implantable graphene bioscaffold which elutes dexamethasone that could accommodate islets and adipose tissue–derived mesenchymal stem cells.
    [Science Advances]

    Full Article

    A Recurring Chemogenetic Switch for Chimeric Antigen Receptor T Cells

    By embedding the hepatitis C virus NS3 protease between the single-chain variable fragment and the hinge domain, investigators showed that the display of anti-CD19 single-chain variable fragment on CAR-T cells was positively correlated to the presence of a clinical hepatitis C virus NS3 protease inhibitor asunaprevir.
    [Angewandte Chemie-International Edition]

    Abstract

    Genetic-Code-Expanded Cell-Based Therapy for Treating Diabetes in Mice

    Scientists engineered a genetic code expansion-based therapeutic system, termed noncanonical amino acids (ncAAs)-triggered therapeutic switch, to achieve fast therapeutic protein expression in response to cognate ncAAs at the translational level.
    [Nature Chemical Biology]

    AbstractGraphical Abstract

    A Novel CD34-Derived Hinge for Rapid and Efficient Detection and Enrichment of CAR T-cells

    For establishing a novel hinge derived from human CD34, researchers systematically tested CD34 fragments of different lengths, all containing the binding site of the QBend-10 monoclonal antibody, in a FMC63-based CD19 CAR lentiviral construct.
    [Molecular Therapy-Oncolytics]

    AbstractFull ArticleGraphical Abstract

    Visualizing CAR-T Cell Immunotherapy Using 3 Tesla Fluorine-19 MRI

    NSG mice received subcutaneous injections of CD19+ human B cell leukemia cells expressing firefly luciferase in their left hind flank.
    [Molecular Imaging and Biology]

    Full Article

    Antigen Multimers: Specific, Sensitive, Precise, and Multifunctional High-Avidity CAR-Staining Reagents

    Investigators developed tetrameric and dodecameric forms of a multifunctional and extensible category of high-avidity CAR-staining reagents: antigen multimers.
    [Matter]

    AbstractGraphical Abstract

    Development of Allogeneic HSC-Engineered iNKT Cells for Off-the-Shelf Cancer Immunotherapy

    By combining hematopoietic stem cell (HSC) gene engineering and in vitro differentiation, scientists generated human allogeneic HSC-engineered invariant natural killer T cells at high yield and purity.
    [Cell Reports Medicine]

    Full ArticleGraphical Abstract
    Connect with us via LiveChat to ask your scientific support questions
    REVIEWS

    Exploiting T Cell Signaling to Optimize Engineered T Cell Therapies

    The authors synthesize recent findings on T cell antigen receptor and CAR signaling and highlights the potential strategies of T cell engineering by signaling refinement.
    [Trends in Cancer]

    Abstract

    Classification and Characteristics of Mesenchymal Stem Cells and Its Potential Therapeutic Mechanisms and Applications against Ischemic Stroke

    Mesenchymal stem cell (MSC) transplantation therapy, which can trigger neuronal regeneration and repair, has been considered as a significant advance in treatment of ischemic stroke.
    [Stem Cells International]

    Full Article
    INDUSTRY AND POLICY NEWS

    SCG Cell Therapy Collaborates with the Cell Therapy Facility at Health Sciences Authority to Validate Processing Methods for T Cell Therapy Manufacturing

    Singapore-based SCG Cell Therapy Pte Ltd has signed an agreement with the Cell Therapy Facility of Singapore Health Sciences Authority for the evaluation and validation of SCG’s proprietary cell therapy manufacturing process to develop a new treatment option for patients with Hepatitis B virus related hepatocellular carcinoma.
    [Singapore Health Sciences Authority]

    Press Release

    EdiGene Enters Research Collaboration with the University of Wisconsin-Madison on In Vivo RNA Editing Therapies

    EdiGene, Inc. has entered into a research collaboration with the University of Wisconsin–Madison as part of the company’s effort of translating proprietary LEAPER™ RNA editing technology into in vivo therapies.
    [EdiGene, Inc.]

    Press Release

    CRISPR Therapeutics and ViaCyte, Inc. to Start Clinical Trial of the First Gene-Edited Cell Replacement Therapy for Treatment of Type 1 Diabetes

    CRISPR Therapeutics,Inc. and ViaCyte, Inc., announced that Health Canada has approved the companies’ Clinical Trial Application for VCTX210, an allogeneic, gene-edited, immune-evasive, stem cell-derived therapy for the treatment of type 1 diabetes. Initiation of patient enrollment is expected by year-end.
    [CRISPR Therapeutics, Inc.]

    Press Release
    FEATURED EVENT

    Stem Cell Society Singapore Symposium 2021

    December 8 – 9, 2021
    Virtual

    > See All Events

    JOB OPPORTUNITIES

    Scientific Researcher – Cancer Immunology

    Genentech – San Francisco, California, United States

    Scientific Researcher – Cancer Immunology

    Genentech – San Francisco, California, United States

    Research Associate – Cancer, Immunity, and Stem Cell Biology

    UC San Diego Health – La Jolla, California, United States

    Scientific Researcher – Cancer Immunology

    Genentech – San Francisco, California, United States

    Scientist – Gene Therapy Research

    Sarepta Therapeutics, Inc. – Columbus, Ohio, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Cell Therapy News Twitter